Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) shares dropped 14.6% during trading on Monday . The stock traded as low as $0.40 and last traded at $0.40. Approximately 1,000 shares traded hands during trading, an increase of 21% from the average daily volume of 828 shares. The stock had previously closed at $0.47.
Defence Therapeutics Stock Performance
The firm has a 50-day simple moving average of $0.54 and a 200 day simple moving average of $0.83.
About Defence Therapeutics
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Featured Articles
- Five stocks we like better than Defence Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- The How and Why of Investing in Gold Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Insider Trading – What You Need to Know
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
